NCT03183297View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001

PHASE1UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

October 31, 2017

Study Completion Date

December 31, 2017

Conditions
Veisalgia
Interventions
DRUG

JMI-001

JMI-001, a combination product of naproxen and fexofenadine

DRUG

Naproxen

Naproxen sodium 220mg

DRUG

Fexofenadine

Fexofenadine 60mg

DRUG

placebo

placebo comparator

Sponsors
All Listed Sponsors
lead

Sen-Jam Pharmaceutical

OTHER

NCT03183297 - Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001 | Biotech Hunter | Biotech Hunter